tradingkey.logo

Calquence® Plus Venetoclax Approved In The US For Patients With Chronic Lymphocytic Leukemia In The 1St-Line Setting

ReutersFeb 20, 2026 12:19 PM

- AstraZeneca PLC AZN.L:

  • CALQUENCE® PLUS VENETOCLAX APPROVED IN THE US AS FIRST ALL-ORAL, FIXED-DURATION COMBINATION FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE 1ST-LINE SETTING

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI